Nichi-Iko Pharmaceutical Co. agreed to buy Sagent Pharmaceuticals Inc. (Nasdaq: SGNT) for $736 million in cash, allowing the Japanese company to build its presence in the U.S. market as it looks to become one of the world’s top manufacturers of generic medicines.

In other mid-market generic pharmaceutical deals:  Perrigo Co. (NYSE: PRGO) purchased generic forms of Retin-A, often prescribed as an anti-aging or acne-treatment skin cream, from Matawan Pharmaceuticals LLC, and Takeda Pharmaceutical Co. formed a partnership with Teva Pharmaceutical Industries Ltd. to sell generic drugs and certain off-patent medicines in Japan.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.